Skip to main content
SpringerLink
Log in

EBV Lymphoproliferative Disease after Transplantation

  • Chapter
Book cover Hematopoietic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

  • 1300 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu.Rev.Med 2005;56:29–44.

    Article  PubMed  CAS  Google Scholar 

  2. Loren AW, Porter DL, Stadtmauer EA et al. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 2003;31:145–155.

    Article  PubMed  CAS  Google Scholar 

  3. Weinstock DM, Ambrossi GG, Brennan C et al. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006;37:539–546.

    Article  PubMed  CAS  Google Scholar 

  4. Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633–3639.

    PubMed  CAS  Google Scholar 

  5. Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999;94:2208–2216.

    PubMed  CAS  Google Scholar 

  6. Socie G, Curtis RE, Deeg HJ et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin.Oncol. 2000;18:348–357.

    PubMed  CAS  Google Scholar 

  7. Gerritsen EJ, Stam ED, Hermans J et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transpl. 1996;18:377–382.

    CAS  Google Scholar 

  8. Rooney CM, Smith CA, Ng CYC et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549–1555.

    PubMed  CAS  Google Scholar 

  9. Gustafsson A, Levitsky V, Zou JZ et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoprolif-erative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000;95:807–814.

    PubMed  CAS  Google Scholar 

  10. Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000;95:1502–1505.

    PubMed  CAS  Google Scholar 

  11. Faye A, Quartier P, Reguerre Y et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001;115:112–118.

    Article  PubMed  CAS  Google Scholar 

  12. Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004;103:3979–3981.

    Article  PubMed  CAS  Google Scholar 

  13. Weinstock DM, Ambrossi GG, Brennan C et al. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006;37:539–546.

    Article  PubMed  CAS  Google Scholar 

  14. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multi-center phase 2 study. Blood 2006;107:3053–3057.

    Article  PubMed  CAS  Google Scholar 

  15. Rooney CM, Loftin SK, Holladay MS et al. Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease. Br J Haematol 1995;89:98–103.

    PubMed  CAS  Google Scholar 

  16. Weinstock DM, Ambrossi GG, Brennan C et al. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006;37:539–546.

    Article  PubMed  CAS  Google Scholar 

  17. Stevens SJ, Verschuuren EA, Pronk I et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients 1. Blood 2001;97:1165–1171.

    Article  PubMed  CAS  Google Scholar 

  18. Hsu JL, Glaser SL. Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev.Oncol.Hematol. 2000;34:27–53.

    Article  PubMed  CAS  Google Scholar 

  19. Rickinson AB, Kieff E. Epstein-Barr Virus. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams & Williams; 2001: 2575–2628.

    Google Scholar 

  20. Cohen JI. Epstein-Barr virus infection. N.Engl.J.Med. 2000;343:481–492.

    Article  PubMed  CAS  Google Scholar 

  21. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 1997;15:405–431.

    Article  PubMed  CAS  Google Scholar 

  22. Callan MF, Tan L, Annels N et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J.Exp. Med. 1998;187:1395–1402.

    Article  PubMed  CAS  Google Scholar 

  23. Munz C, Bickham KL, Subklewe M et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J.Exp.Med. 2000;191:1649–1660.

    Article  PubMed  CAS  Google Scholar 

  24. Nikiforow S, Bottomly K, Miller G. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol. 2001;75:3740–3752.

    Article  PubMed  CAS  Google Scholar 

  25. Heller KN, Gurer C, Munz C. Virus-specific CD4+ T cells: ready for direct attack. J.Exp.Med. 2006;203:805–808.

    Article  PubMed  CAS  Google Scholar 

  26. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N.Engl.J.Med. 2004;350:1328–1337.

    Article  PubMed  CAS  Google Scholar 

  27. Heslop HE. Biology and treatment of epstein-barr virus-associated non-hodgkin lymphomas. Hematology.(Am.Soc.Hematol.Educ.Program.) 2005260–266.

    Google Scholar 

  28. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 2002;12:431–441.

    Article  CAS  Google Scholar 

  29. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat.Rev.Immunol. 2003;3:801–812.

    Article  PubMed  CAS  Google Scholar 

  30. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat.Rev. Cancer 2005;5:251–262.

    Article  PubMed  CAS  Google Scholar 

  31. Timms JM, Bell A, Flavell JR et al. Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet 2003;361:217–223.

    Article  PubMed  Google Scholar 

  32. Capello D, Cerri M, Muti G et al. Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood 2003;102:3775–3785.

    Article  PubMed  CAS  Google Scholar 

  33. Yao QY, Ogan P, Rowe M et al. Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer 1989;43:67–71.

    Article  PubMed  CAS  Google Scholar 

  34. Lee TC, Savoldo B, Barshes NR et al. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lympho-proliferative disorder in paediatric liver transplant recipients. Clin.Transplant. 2006;20:389–393.

    Article  PubMed  Google Scholar 

  35. Dierksheide JE, Baiocchi RA, Ferketich AK et al. IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. Blood 2005;105:1558–1565.

    Article  PubMed  CAS  Google Scholar 

  36. Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol Oncol 2005;23:61–67.

    Article  PubMed  Google Scholar 

  37. Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633–3639.

    PubMed  CAS  Google Scholar 

  38. Hoshino Y, Kimura H, Tanaka N et al. Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. Br J Haematol 2001;115:105–111.

    Article  PubMed  CAS  Google Scholar 

  39. Cohen J, Gandhi M, Naik P et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005;129:229–239.

    Article  PubMed  Google Scholar 

  40. Cesaro S, Murrone A, Mengoli C et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005;128:224–233.

    Article  PubMed  Google Scholar 

  41. Brunstein CG, Weisdorf DJ, DeFor T et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a non-myeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006;108:2874–2880.

    Article  PubMed  CAS  Google Scholar 

  42. Hale G, Waldmann H, for CAMPATH users. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. Blood 1998;91:3079–3083.

    PubMed  CAS  Google Scholar 

  43. Gross TG, Hinrichs SH, Davis JR et al. Depletion of EBV-infected cells in donor marrow by counterflow elutriation. Exp Hematol 1998;26:395–399.

    PubMed  CAS  Google Scholar 

  44. Cavazzana-Calvo M, Bensoussan D, Jabado N et al. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T- depleted bone marrow transplantation. Br J Haematol 1998;103:543–551.

    Article  PubMed  CAS  Google Scholar 

  45. Hauke RJ, Greiner TC, Smir BN et al. Epstein-Barr virus-associated lympho-proliferative disorder after autolgous bone marrow transplantation: report of two cases. Bone Marrow Transplant 1998;21:1271–1274.

    Article  PubMed  CAS  Google Scholar 

  46. Nash RA, Dansey R, Storek J et al. Epstein-Barr virus-associated posttransplan-tation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol.Blood Marrow Transplant. 2003;9:583–591.

    Article  PubMed  Google Scholar 

  47. Barker JN, Martin PL, Coad JE et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 2001;7:395–399.

    Article  PubMed  CAS  Google Scholar 

  48. Brunstein CG, Weisdorf DJ, DeFor T et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a non-myeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006;108:2874–2880.

    Article  PubMed  CAS  Google Scholar 

  49. Deeg HJ, Socie G. Malignancies after hemopoietic stem cell transplantation: many questions, some answers. Blood 1998;91:1833–1844.

    PubMed  CAS  Google Scholar 

  50. Knowles DM, Cesarman E, Chadburn A et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplan-tation lymphoproliferative disorders. Blood 1995;85:552–565.

    PubMed  CAS  Google Scholar 

  51. Orazi A, Hromas RA, Neiman RS et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Path 1997;107:419–429.

    PubMed  CAS  Google Scholar 

  52. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J.Clin.Oncol. 1999;17:3835–3849.

    Google Scholar 

  53. Paya C V, Fung JJ, Nalesnik MA et al. Epstein-Barr virus-induced posttrans-plant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68:1517–1525.

    Article  PubMed  CAS  Google Scholar 

  54. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J.Clin.Oncol. 1999;17:3835–3849.

    PubMed  CAS  Google Scholar 

  55. Tsai DE, Hardy CL, Tomaszewski JE et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001;71:1076–1088.

    Article  PubMed  CAS  Google Scholar 

  56. Weinstock DM, Ambrossi GG, Brennan C et al. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006;37:539–546.

    Article  PubMed  CAS  Google Scholar 

  57. Yang J, Tao Q, Flinn IW et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000;96:4055–4063.

    PubMed  CAS  Google Scholar 

  58. van Baarle D, Hovenkamp E, Callan MF et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 2001;98:146–155.

    Article  PubMed  Google Scholar 

  59. Kimura H, Morita M, Yabuta Y et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999;37:132–136.

    PubMed  CAS  Google Scholar 

  60. Lucas KG, Burton RL, Zimmerman SE et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998;91:3654–3661.

    PubMed  CAS  Google Scholar 

  61. Weinstock DM, Ambrossi GG, Brennan C et al. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006;37:539–546.

    Article  PubMed  CAS  Google Scholar 

  62. Niesters HG, van Esser J, Fries E et al. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J.Clin.Microbiol. 2000;38:712–715.

    PubMed  CAS  Google Scholar 

  63. van Esser JW, van der HB, Meijer E et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell—depleted SCT. Blood 2001;98:972–978.

    Article  PubMed  Google Scholar 

  64. Greenfield HM, Gharib MI, Turner AJ et al. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention? Pediatr.Blood Cancer 2006;47:200–205.

    Article  Google Scholar 

  65. Rose C, Green M, Webber S et al. Pediatric solid-organ transplant recipients carry chronic loads of epstein-barr virus exclusively in the immunoglobulin d-negative b-cell compartment. J. Clin. Microbiol. 2001;39:1407–1415.

    Article  PubMed  CAS  Google Scholar 

  66. Gratama JW, Cornelissen JJ. Clinical utility of tetramer-based immune monitoring in allogeneic stem cell transplantation. BioDrugs. 2003;17:325–338.

    Article  PubMed  CAS  Google Scholar 

  67. Meij P, van Esser JW, Niesters HG et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003;101:4290–4297.

    Article  PubMed  CAS  Google Scholar 

  68. Swinnen LJ. Treatment of organ transplant-related lymphoma. Hematol Oncol Clin North Am 1998;11:963–973.

    Article  Google Scholar 

  69. Cesaro S, Murrone A, Mengoli C et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005;128:224–233.

    Article  PubMed  Google Scholar 

  70. Gross TG, Steinbuch M, DeFor T et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999;23:251–258.

    Article  PubMed  CAS  Google Scholar 

  71. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 1994;330:1185–1191.

    Article  PubMed  CAS  Google Scholar 

  72. O'Reilly RJ, Small TN, Papadopoulos E et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunological Reviews 1997;157:195–216.

    Article  PubMed  Google Scholar 

  73. Sasahara Y, Kawai S, Itano M et al. Epstein-Barr virus-associated lymphoprolif-erative disorder after unrelated bone marrow transplantation in a young child with Wiskott-Aldrich syndrome. Pediatr Hematol Oncol 1998;15:347–352.

    Article  PubMed  CAS  Google Scholar 

  74. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994;331:679–680.

    Article  PubMed  CAS  Google Scholar 

  75. Nagafuji K, Eto T, Hayashi S et al. Donor lymphocyte transfusion for the treatment of Epstein-Barr virus-associated lymphoproliferative disorder of the brain. Bone Marrow Transplant 1998;21:1155–1158.

    Article  PubMed  CAS  Google Scholar 

  76. Imashuku S, Goto T, Matsumura T et al. Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD). Bone Marrow Transplant 1998;20:337–340.

    Article  Google Scholar 

  77. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia. Science 1997;276:1719–1724.

    Article  PubMed  CAS  Google Scholar 

  78. Berger C, Flowers ME, Warren EH et al. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006;107:2294–2302.

    Article  PubMed  CAS  Google Scholar 

  79. Straathof KC, Pule MA, Yotnda P et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005;105:4247–4254.

    Article  PubMed  CAS  Google Scholar 

  80. Thomis DC, Marktel S, Bonini C et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001;97:1249–1257.

    Article  PubMed  CAS  Google Scholar 

  81. Serafini M, Manganini M, Borleri G et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum.Gene Ther. 2004;15:63–76.

    Article  PubMed  CAS  Google Scholar 

  82. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238–241.

    Article  PubMed  CAS  Google Scholar 

  83. Riddell SR, Greenberg PD. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J Antimicrob Chemother 2000;45 Suppl T3:35–43.

    Article  PubMed  CAS  Google Scholar 

  84. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038–1044.

    Article  PubMed  CAS  Google Scholar 

  85. Heslop HE, Rooney CM. Adoptive immunotherapy of EBV lymphoproliferative diseases. Immunological Reviews 1997;157:217–222.

    Article  PubMed  CAS  Google Scholar 

  86. Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Medicine 1996;2:551–555.

    Article  PubMed  CAS  Google Scholar 

  87. Pakakasama S, Eames GM, Morriss MC et al. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation 2004;78:755–757.

    Article  PubMed  Google Scholar 

  88. Gottschalk S, Ng CYC, Smith CA et al. An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 2001;97:835–843.

    Article  PubMed  CAS  Google Scholar 

  89. Goulder PJ, Brander C, Tang Y et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001;412:334–338.

    Article  PubMed  CAS  Google Scholar 

  90. Furukawa Y, Kubota R, Tara M et al. Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia. Blood 2001;97:987–993.

    Article  PubMed  CAS  Google Scholar 

  91. Koehne G, Gallardo HF, Sadelain M et al. Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood 2000;96:109–117.

    PubMed  CAS  Google Scholar 

  92. Sun Q, Pollok KE, Burton RL et al. Simultaneous ex vivo expansion of cytomega-lovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphob-lastoid cell lines expressing cytomegalovirus pp65. Blood 1999;94:3242–3250.

    PubMed  CAS  Google Scholar 

  93. Regn S, Raffegerst S, Chen X et al. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Bone Marrow Transplant. 2001;27:53–64.

    Article  PubMed  CAS  Google Scholar 

  94. Leen AM, Myers GD, Sili U et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immuno-compromised individuals. Nat.Med. 2006;12:1160–1166.

    Article  PubMed  CAS  Google Scholar 

  95. Montagna D, Yvon E, Calcaterra V et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood 1999;93:3550–3557.

    PubMed  CAS  Google Scholar 

  96. Amrolia PJ, Muccioli-Casadei G, Yvon E et al. Selective depletion of donor allo-reactive T-cells without loss of anti- viral or anti-leukemic responses. Blood 2003

    Google Scholar 

  97. Amrolia PJ, Muccioli-Casadei G, Huls H et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006;108:1797–1808.

    Article  PubMed  CAS  Google Scholar 

  98. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002;360:130–137.

    Article  PubMed  Google Scholar 

  99. Solomon SR, Mielke S, Savani BN et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005;106:1123–1129.

    Article  PubMed  CAS  Google Scholar 

  100. Nalesnik MA, Rao AS, Furukawa H et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1998;63:1200–1205.

    Article  Google Scholar 

  101. Fischer A, Blanche S, LeBidois J et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N.Engl.J.Med. 1991;324:1451–1456.

    Article  PubMed  CAS  Google Scholar 

  102. Levy R. A perspective on monoclonal antibody therapy: where we have been and where we are going. Semin Hematol 2000;37:43–46.

    Article  PubMed  CAS  Google Scholar 

  103. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188–2195.

    PubMed  CAS  Google Scholar 

  104. Maloney GD. Monoclonal antibodies in lymphoid neoplasia: principles for optimal combined therapy. Semin Hematol 2000;37:17–26.

    Article  PubMed  CAS  Google Scholar 

  105. Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000;11 Suppl 1:113–116.

    Article  PubMed  Google Scholar 

  106. Savoldo B, Rooney CM, Quiros-Tejeira RE et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am.J Transplant. 2005;5:566–572.

    Article  PubMed  CAS  Google Scholar 

  107. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053–3057.

    Article  PubMed  CAS  Google Scholar 

  108. Carpenter PA, Appelbaum FR, Corey L et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002;99:2712–2719.

    Article  PubMed  CAS  Google Scholar 

  109. van Esser JW, Niesters HG, van der HB et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364–4369.

    Article  PubMed  Google Scholar 

  110. Gruhn B, Meerbach A, Haefer R, Zell R, Berndt A, Kosmehl H, Wutzler P, Zintl F. Early diagnosis and preemptive therapy of Epstein-Barr virus-associated lympho-proliferative disease following hematopoietic stem cell transplantation [abstract]. Blood 2001;98:suppl 1:393a.

    Google Scholar 

  111. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression [In Process Citation]. Clin Cancer Res 1999;5:611–615.

    PubMed  CAS  Google Scholar 

  112. Verschuuren EA, Stevens SJ, van Imhoff GW et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002;73:100–104.

    Article  PubMed  CAS  Google Scholar 

  113. Haddad E, Paczesny S, Leblond V et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1–2 clinical trial. Blood 2001;97:1590–1597.

    Article  PubMed  CAS  Google Scholar 

  114. Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633–3639.

    PubMed  CAS  Google Scholar 

  115. Faye A, Van Den Abeele T, Peuchmaur M et al. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998;352:1285.

    Article  PubMed  CAS  Google Scholar 

  116. Greenfield HM, Gharib MI, Turner AJ et al. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention? Pediatr.Blood Cancer 2006;47:200–205.

    Article  Google Scholar 

  117. Gruhn B, Meerbach A, Hafer R et al. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31:1023–1025.

    Article  PubMed  CAS  Google Scholar 

  118. Weinstock DM, Ambrossi GG, Brennan C et al. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006;37:539–546.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by National Institutes of Health grants RO1 CA61384 and U54HL081007 and the GCRC at Baylor College of Medicine (NIH-RR00188). S.G. is the recipient of a Doris Duke clinical scientist development award. H. E. H. is the recipient of a Doris Duke distinguished clinical scientist award.

Author information

Authors and Affiliations

  1. Center for Cell and Gene Therapy, Texas Children's Cancer Center, Departments of Pediatrics, Medicine, Immunology, and Molecular Virology and Microbiology, Baylor College of Medicine, The Methodist Hospital,, Houston, TX

    Stephen Gottschalk

  2. Center for Cell and Gene Therapy, Texas Children's Cancer Center, Departments of Pediatrics, Medicine, Immunology, and Molecular Virology and Microbiology, Baylor College of Medicine, The Methodist Hospital,, Houston, TX

    Cliona M. Rooney

  3. Division of Center for Cell and Gene Therapy, The Methodist Hospital and Texas Children's Hospital, Houston, TX

    Helen E. Heslop

Authors
  1. Stephen Gottschalk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cliona M. Rooney
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helen E. Heslop
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, DFCI D1B30, Boston, MA, 02115, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Gottschalk, S., Rooney, C.M., Heslop, H.E. (2008). EBV Lymphoproliferative Disease after Transplantation. In: Soiffer, R.J. (eds) Hematopoietic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-438-4_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-438-4_20

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-05-3

  • Online ISBN: 978-1-59745-438-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation